Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals (NASDAQ: APLS) has announced its participation in two upcoming investor conferences in May 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apellis Pharmaceuticals (NASDAQ: APLS) has announced its participation in two upcoming investor conferences in May 2025. The company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on May 13 at 8:40 a.m. PT, and another fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on May 27 at 2:30 p.m. ET. Both events will be webcast live and available on the company's website under the \"Events and Presentations\" page, with replays accessible for approximately 90 days after the events.
Details
News Market Reaction – APLS
The recorded move for APLS in the trading session of this news was -4.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in the following May investor conferences:
- BofA Securities 2025 Healthcare Conference: Fireside chat on Tuesday, May 13, 2025 at 8:40 a.m. PT
- Stifel 2025 Virtual Ophthalmology Forum: Fireside chat on Tuesday, May 27, 2025 at 2:30 p.m. ET
The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Neil Carnahan
neil.carnahan@apellis.com
207.318.4494
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.